|Bid||139.17 x 800|
|Ask||139.42 x 800|
|Day's Range||137.13 - 140.17|
|52 Week Range||32.80 - 176.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Sarepta Therapeutics (SRPT), a commercial-stage biopharmaceutical company, develops unique RNA1-targeted therapeutics, gene therapies, and other medicines for neuromuscular diseases. Sarepta is expected to release its Q2 2018 earnings on July 18. The chart below shows Sarepta’s revenue and EPS since Q1 2017, and estimates for Q2 2018.
Gene therapy companies are looking to advance the technology, creating potentially curative treatments for genetic diseases.
Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
On July 6, Gemphire Therapeutics (GEMP) stock closed at $8.09, ~70% higher than its 52-week low of $4.75 on May 7. After Gemphire announced positive clinical trial results on June 28, its stock price started to rise and closed at $5.24, and on June 29, it rose ~94.47% to $10.19.
The Food and Drug Administration’s approval of Sarepta Therapeutic’s Duchenne drug is a teachable moment for 21st-century regulatory science (“A Risky Drug Approval Lesson”, Review and Outlook, July 5). The FDA cannot regulate drug trials properly without factoring in patients’ opinions. Is that calculation reproducible across therapeutic categories? istock/getty images View of human skeletal muscle under a microscope.
Full details of the study will be announced at the Alzheimer's Association International Conference (AAIC) on July 22-26 or possibly at a later conference in October. which gapped up big on news in mid-June.
In the week that ended on June 29, Vertex Pharmaceuticals (VRTX) stock closed at $169.96, which represented a ~7% rise from its previous week’s close of $159.76. On June 29, Vertex Pharmaceuticals’ stock price rose 15.16% to reach $169.96 from its previous day’s close of $147.59. In June, Vertex Pharmaceuticals announced that its cystic fibrosis drug Orkambi would be reimbursed in Sweden.
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern.
Short interest is moderate for SRPT with between 5 and 10% of shares outstanding currently on loan. The net inflows of $3.54 billion over the last one-month into ETFs that hold SRPT are not among the highest of the last year and have been slowing.
Some welcome news arrived recently for boys with a condition called Duchenne muscular dystrophy. A new therapy is showing promising results, and it raises a question for the Food and Drug Administration: What if society had missed this moment? In late June Sarepta Therapeutics, a biotech company, released data on a gene therapy for Duchenne, a disease that weakens muscles and organ function.
Three business that offer practical investment opportunities whether cryptocurrencies form a speculative bubble again or not.
So far the holiday trading party isn't too exciting. The indices are green and breadth is quite strong with about 4450 gainers to just 1800 losers but the pockets of momentum are limited and the FAANG names aren't participating.
On June 27, Summit Therapeutics (SMMT) announced that its phase two PhaseOut DMD trial evaluating investigational utrophin modulator ezutromid in the Duchenne muscular dystrophy (or DMD) indication failed to meet its primary endpoint. This news also affected the stock prices of Sarepta Therapeutics (SRPT), which dropped 4.6% and reached $129.3 on June 27. In the absence of the DMD program, Summit Therapeutics is heavily dependent on the success of its late-stage investigational precision antibiotic, ridinilazole, which is being developed as a front-line therapy for patients suffering from clostridium difficile infections.
The Street grew more bullish on Solid Biosciences Inc (NASDAQ: SLDB ) last week following progress announcements on Solid and peer candidates. At least three analysts raised their valuation targets: The ...
On June 19, Sarepta Therapeutics (SRPT) announced positive preliminary results from its phase one part 2a gene therapy micro dystrophin trial on treating patients with Duchenne muscular dystrophy (or DMD) from the first three children dosed. DMD generally affects boys, and death typically occurs before age 30 in DMD patients. In all three patients, biopsies done on the 90th day showed robust micro dystrophin expression in muscle as measured by all methods.
By applying its proprietary platform technologies, Sarepta Therapeutics (SRPT) is able to target a range of diseases and disorders. The company’s first product on the US market, the Exondys 51 injection, received accelerated approval from the US FDA in September 2016. The injection is targeted for treating Duchenne muscular dystrophy (or DMD).
Sarepta Therapeutics (SRPT) and Myonexus Therapeutics entered into a warrant to purchase Myonexus common stock on May 3. This agreement gives Sarepta the exclusive option to acquire Myonexus. Myonexus completes a successful biopsy analysis on all the patients in cohort two capable of providing a biopsy at the end of 60 days of Myonexus’s phase one and two clinical trial of MYO-101.
The company incurred costs of sales of $5.6 million in Q1 2018 as compared with $223,000 in Q1 2017. Sarepta Therapeutics incurred research and development expenses of $46.2 million in Q1 2018 as compared with $29.1 million in Q1 2017. The selling, general, and administrative expenses incurred by the company also grew from $26.2 million in Q1 2017 to $43.3 million in Q1 2018.
Sarepta Therapeutics (SRPT) spent $35.7 million on operating activities in Q1 2018. In comparison, the company spent $57.9 million in operating activities in Q1 2017. In Q1 2018, Sarepta Therapeutics spent $14.3 million on investing activities. It generated $210 million from investing activities in Q1 2017. Sarepta spent $12.2 million on the purchase of property and equipment in Q1 2018 as compared with $4.5 million in Q1 2017. In Q1 2017 the company received $90.7 million from maturities of available for sale securities and restricted investment. ...